# US 2005/0038231 A1 · Reducing protein a leaching during protein a affinity chromatography

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0038231 A1
- Document ID: US20050038231A1
- Status: Published application
- Kind: A1
- Application number: 10/877,532
- Filed: 2004-06-24
- Published: 2005-02-17
- Earliest claimed: 2003-07-28
- Assignees: Genentech, Inc.
- Inventors: Robert Fahrner; Amy Laverdiere; Paul McDonald; Rhona O'Leary
- Web page: https://patentgrep.com/patent/US20050038231A1

## CPC

- C07K 16/065: {Purification, fragmentation}
- B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography}
- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2845: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- C07K 16/32: against translation products of oncogenes
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography.

## Claims

### Claim 1

A method of purifying a protein which comprises a CH2/CH3 region, comprising reducing the temperature of a composition comprising the protein and one or more impurities subjected to protein A affinity chromatography in the range from about 3° C. to about 20° C., wherein protein A leaching is reduced.

### Claim 2 (depends on 1)

The method of claim 1 further comprising measuring leached protein A in a composition comprising the protein which is recovered from the protein A affinity chromatography.

### Claim 3 (depends on 1)

The method of claim 1 which comprises reducing the temperature of the composition prior to subjecting the composition to protein A affinity chromatography.

### Claim 4 (depends on 1)

The method of claim 1 further comprising exposing the composition subjected to protein A affinity chromatography to a protease inhibitor.

### Claim 5 (depends on 1)

The method of claim 1 wherein the protein is an antibody.

### Claim 6 (depends on 5)

The method of claim 5 wherein the antibody binds an antigen selected from the group consisting of HER2, vascular endothelial growth factor (VEGF), IgE, CD20, CD40, CD11a, tissue factor (TF), prostate stem cell antigen (PSCA), interleukin-8 (IL-8), epidermal growth factor receptor (EGFR), HER3, HER4, α4β7 or α5β3.

### Claim 7 (depends on 5)

The method of claim 5 wherein the antibody is selected from the group consisting of Trastuzumab, humanized 2C4, humanized CD11a antibody, and humanized VEGF antibody.

### Claim 8 (depends on 5)

The method of claim 5 wherein the antibody binds HER2 antigen.

### Claim 9 (depends on 8)

The method of claim 8 wherein the antibody is Trastuzumab or humanized 2C4.

### Claim 10 (depends on 1)

The method of claim 1 wherein the protein is an immunoadhesin.

### Claim 11 (depends on 10)

The method of claim 10 wherein the immunoadhesin is a TNF receptor immunoadhesin.

### Claim 12

A method of purifying a protein which comprises a CH2/CH3 region by protein A affinity chromatography comprising:
(a) subjecting the protein to protein A affinity chromatography and measuring leached protein A in a composition comprising the protein which is recovered from the protein A affinity chromatography;
(b) if protein A leaching is detected in step (a), reducing the temperature of a composition comprising the protein and one or more impurities subjected to protein A affinity chromatography in the range from about 3° C. to about 20° C., such that protein A leaching is reduced.

### Claim 13

A method for reducing leaching of protein A during protein A affinity chromatography comprising reducing protease activity in a composition subjected to protein A affinity chromatography, wherein the composition comprises a protein which comprises a CH2/CH3 region and one or more proteases.

### Claim 14 (depends on 13)

The method of claim 13 which comprises reducing temperature of the composition subjected to the protein A affinity chromatography in order to reduce the protease activity.

### Claim 15 (depends on 13)

The method of claim 13 comprising exposing the composition subjected to protein A affinity chromatography to a protease inhibitor in order to reduce the protease activity.

### Claim 16 (depends on 15)

The method of claim 15 wherein the protease inhibitor is EDTA or 4-(2-aminoethyl)-benzenesulfonyl-fluoride, hydrochloride (AEBSF).

### Claim 17 (depends on 15)

The method of claim 15 further comprising reducing temperature of the composition subjected to the protein A affinity chromatography in order to further reduce the protease activity.

### Claim 18 (depends on 13)

The method of claim 13 comprising lowering pH of the composition subjected to protein A affinity chromatography.

### Claim 19 (depends on 18)

The method of claim 18 wherein the composition subjected to protein A chromatography is lowered to a pH in the range from about 2.5 to about 3.5.
